X
With all eyes on IO, Tagrisso could be AZ’s ace card
https://pharmaphorum.com/news/io-tagrisso-az-ace-card/
NSCLC
Merck soars on Keytruda combination filing
Approval by May could put Keytruda in pole position
Can Keytruda beat Opdivo to full UK access in lung cancer?
A decisive moment in lung cancer treatment is nearing
BMS and Nektar to pair Opdivo with natural killer cell drug
BMS and Nektar’s combination latest in frenzied immunotherapy field
Merck makes its move: Keytruda filed for first line lung cancer
Merck steals a march on rival BMS.
BMS’ Opdivo stumbles in lung cancer, but could still maintain lead
Analysts expect Opdivo to recover via combination trials
New data supports key AZ cancer drug
Tagrisso could help revive sales after patent losses.
Scotland’s Opdivo decision sparks funding row
Patients in Scotland will receive lung cancer drug, those in England will not.
AstraZeneca, Genentech fund PatientsLikeMe research into cancer patient experiences
PatientsLikeMe is working with AstraZeneca and Roche to find about more about the experiences of people being treated for lung cancer